Pharma stock prices fall 5% on Trump drug price reforms by mid-2026

Pharmaceutical companies like Eli Lilly and Merck face regulatory and pricing pressure from Trump’s reforms. Investors anticipate lower profit margins, leading to a broad sell-off in the sector. The decline would reflect market skepticism about pharma’s ability to offset losses.

Implied probability (Yes)

70%